Company intelligence / Profile preview
Soricimed Biopharma Inc.
Moncton, New Brunswick, Canadasoricimed.com ↗
- Ownership
- Private
- Employees
- ~12
- Development stage
- Phase 1
01
Overview
Lead drug candidate SOR-C13 has completed Phase 1 trials showing safety and tolerability with indications of efficacy. Currently in Phase 1b investigator-initiated trial at MD Anderson Cancer Center. SOR-C13 has received FDA orphan drug status for pancreatic and ovarian cancers.
- Therapeutic areas
- GastroenterologyOncologyWomen's Health
- Modalities
- PeptidesPeptide-Drug Conjugates (PDCs)Peptide Receptor Radionuclide Therapy (PRRT)
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Eisai Inc. (previous collaboration)
Beyond the preview
Go deeper on Soricimed Biopharma Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Soricimed Biopharma Inc..